Feed/Companies/Thryv Therapeutics Inc.

Thryv Therapeutics Inc.

As of 3 Nov 2026, Thryv Therapeutics Inc. has raised $30M across 1 verified round on record; latest: $30 million Series B led by InClin, announced 3 Nov 2026.

BUILT ON

A clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies.

Canada

LATEST ROUND

Series B

$30M · 2026-11-03

RAISED ON RECORD · USD

$30M

across 1 verified round

INVESTORS

1 lead

SOURCES

from 3 publishers

Rounds

[ 1 ]

Series B

$30M

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Round	Amount	Announced	Lead	Buzz
Series B	$30M	2026-11-03	InClin	3 outlets. #47 in Trending
3 sources [ VERIFIED ] read against 3 sources Sources vary only in currency formatting—USD 30 million, $30m, and $30 million; the company’s release is preferred. [ BUILT WITH ]·[ SEARCH ]found on a watched publisher·[ SCRAPE ]3 pages read: prnewswire.com, allsci.com, citybiz.co·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 3 sources

Thryv Therapeutics Inc.

Rounds

Company

Rounds

Sources

Profile

Investors

Thryv Therapeutics Inc.

Rounds

Sources

Series B$30M2026-11-033 sources

Investors

Series B$30M2026-11-038 investors